In lab experiments, the monoclonal antibody cetuximab was shown to bind EGFR with high affinity, which suggested that cetuximab might have a disposition to slow down the progress of colorectal cancer (by blocking EGFR) [34]. The gene discussed is EGFR; the disease is colorectal cancer.